Overview

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Status:
Completed
Trial end date:
2019-05-06
Target enrollment:
Participant gender:
Summary
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd